CervoMed (CRVO) Operating Expenses (2010 - 2026)
CervoMed (CRVO) posted Operating Expenses of $8.1 million for Q1 2026, down 2.75% sequentially from $8.3 million in Q4 2025, and up 12.33% YoY from $7.2 million in Q1 2025.
CervoMed (CRVO) Operating Expenses (2010 - 2026) Analysis & Trends
CervoMed has reported Operating Expenses for 17 years, with the latest figure at $8.1 million in Q1 2026.
- Quarterly Operating Expenses rose 12.33% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.2 million (up 9.75% YoY) and the FY2025 annual result came in at $32.3 million, up 15.51% from the prior year.
- Operating Expenses eased to $8.1 million in Q1 2026 per CRVO's latest filing, from $8.3 million in the prior quarter.
- Over five years, Operating Expenses peaked at $9.4 million in Q4 2024 and troughed at $904054.0 in Q3 2022.
- A 5-year average of $5.5 million and a median of $5.0 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 77.71% in 2022, then jumped 429.5% in 2023.
- Over 5 years, Operating Expenses stood at $938823.0 in 2022, then surged by 429.5% to $5.0 million in 2023, then surged by 89.15% to $9.4 million in 2024, then declined by 11.3% to $8.3 million in 2025, then declined by 2.75% to $8.1 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $8.1 million, $8.3 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | 6.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.68 Mn |
| Mar 31, 2026 | 8.11 Mn |
| Dec 31, 2025 | 8.34 Mn |
| Sep 30, 2025 | 8.37 Mn |
| Jun 30, 2025 | 8.37 Mn |
| Mar 31, 2025 | 7.22 Mn |
| Dec 31, 2024 | 9.40 Mn |
| Sep 30, 2024 | 7.34 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 4.94 Mn |
| Dec 31, 2023 | 4.97 Mn |
| Sep 30, 2023 | 4.20 Mn |
| Jun 30, 2023 | 2.95 Mn |
| Mar 31, 2023 | 2.83 Mn |
| Dec 31, 2022 | 938,823.00 |
| Sep 30, 2022 | 904,054.00 |
| Jun 30, 2022 | 4.25 Mn |
| Mar 31, 2022 | 4.55 Mn |
| Dec 31, 2021 | 3.47 Mn |
| Sep 30, 2021 | 4.05 Mn |